{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T08:41:16Z","timestamp":1790152876402,"version":"4.0.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T00:00:00Z","timestamp":1621900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T00:00:00Z","timestamp":1621900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors have opened a new scenario in the treatment of cancer. These agents can elicit adverse events, which may affect different systems and organs, including the endocrine system. The aims of this study were to evaluate the impact of the anti-PD-1 molecules nivolumab and pembrolizumab on endocrine toxicity and on patient outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective and multicentre study was designed, which involved a total of 251 patients affected by different tumors (mostly non-small cell lung cancer, 68.92% and melanoma, 24.30%) and treated with the PD-1 inhibitors nivolumab (61.35%) or pembrolizumab (38.65%) for up to 60 months. Clinical and biochemical data were recorded until July 31, 2020.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Endocrine toxicity occurred in 70 out of 251 patients (27.89%). It was mostly related to thyroid dysfunction and in 75% of cases occurred within 6 months from the beginning of therapy. A previous endocrine morbidity and female gender were predictors of endocrine toxicity. There was no association between endocrine dysfunction and patient outcome. However, when all toxicities (i.e., endocrine and non endocrine) were considered, a significant association with progression-free survival and overall survival was found.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Thyroid alterations are frequently observed in cancer patients treated with anti PD-1 drugs, particularly in women and in the presence of a previous endocrinopathy. We suggest that regular thyroid assessment should be performed in these patients, especially in the first months of therapy. Finally, the onset of side effects, related to anti PD-1 agents, appears to be associated with a better outcome.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12020-021-02750-w","type":"journal-article","created":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T12:03:07Z","timestamp":1621944187000},"page":"172-179","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Endocrine-related adverse events in a large series of cancer patients treated with anti-PD1 therapy"],"prefix":"10.1007","volume":"74","author":[{"given":"Rossella","family":"Rubino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Marini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giandomenico","family":"Roviello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena Margherita","family":"Presotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isacco","family":"Desideri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Ciardetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Brugia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Pimpinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Antonuzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Mini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Livi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Maggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6417-434X","authenticated-orcid":false,"given":"Alessandro","family":"Peri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,25]]},"reference":[{"key":"2750_CR1","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"F.S. Hodi, S.J. O\u2019Day, D.F. McDermott, R.W. Weber, J.A. Sosman, J.B. Haanen, R. Gonzalez, C. Robert, D. Schadendorf, J.C. Hassel et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711\u2013723 (2010)","journal-title":"N. Engl. J. Med."},{"key":"2750_CR2","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S1470-2045(09)70334-1","volume":"11","author":"JD Wolchok","year":"2010","unstructured":"J.D. Wolchok, B. Neyns, G. Linette, S. Negrier, J. Lutzky, L. Thomas, W. Waterfield, D. Schadendorf, M. Smylie, T. Guthrie Jr et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 11, 155\u2013164 (2010)","journal-title":"Lancet Oncol."},{"key":"2750_CR3","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"S.L. Topalian, F.S. Hodi, J.R. Brahmer, S.N. Gettinger, D.C. Smith, D.F. McDermott, J.D. Powderly, R.D. Carvajal, J.A. Sosman, M.B. Atkins et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443\u20132454 (2012)","journal-title":"N. Engl. J. Med."},{"key":"2750_CR4","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.coi.2013.02.011","volume":"25","author":"A Ribas","year":"2013","unstructured":"A. Ribas, J.D. Wolchok, Combining cancer immunotherapy and targeted therapy. Curr. Opin. Immunol. 25, 291\u2013296 (2013)","journal-title":"Curr. Opin. Immunol."},{"key":"2750_CR5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"J. Larkin, V. Chiarion-Sileni, R. Gonzalez, J.J. Grob, C.L. Cowey, C.D. Lao, D. Schadendorf, R. Dummer, M. Smylie, P. Rutkowski et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N. Engl. J. Med. 373, 23\u201334 (2015)","journal-title":"N. Engl. J. Med."},{"key":"2750_CR6","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","volume":"33","author":"MA Postow","year":"2015","unstructured":"M.A. Postow, M.K. Callahan, J.D. Wolchok, Immune Checkpoint Blockade in Cancer Therapy. J. Clin. Oncol. 33, 1974\u20131982 (2015)","journal-title":"J. Clin. Oncol."},{"key":"2750_CR7","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","volume":"387","author":"L Fehrenbacher","year":"2016","unstructured":"L. Fehrenbacher, A. Spira, M. Ballinger, M. Kowanetz, J. Vansteenkiste, J. Mazieres, K. Park, D. Smith, A. Artal-Cortes, C. Lewanski et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 387, 1837\u20131846 (2016)","journal-title":"Lancet"},{"key":"2750_CR8","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/JCO.2016.67.9761","volume":"34","author":"C Massard","year":"2016","unstructured":"C. Massard, M.S. Gordon, S. Sharma, S. Rafii, Z.A. Wainberg, J. Luke, T.J. Curiel, G. Colon-Otero, O. Hamid, R.E. Sanborn et al. Safety and Efficacy of Durvalumab (MEDI4736), an anti-Programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J. Clin. Oncol. 34, 3119\u20133125 (2016)","journal-title":"J. Clin. Oncol."},{"key":"2750_CR9","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","volume":"389","author":"A Rittmeyer","year":"2017","unstructured":"A. Rittmeyer, F. Barlesi, D. Waterkamp, K. Park, F. Ciardiello, J. von Pawel, S.M. Gadgeel, T. Hida, D.M. Kowalski, M.C. Dols et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389, 255\u2013265 (2017)","journal-title":"Lancet"},{"key":"2750_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1210\/er.2018-00006","volume":"40","author":"LS Chang","year":"2019","unstructured":"L.S. Chang, R. Barroso-Sousa, S.M. Tolaney, F.S. Hodi, U.B. Kaiser, L. Min, Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. Endocr. Rev. 40, 17\u201365 (2019)","journal-title":"Endocr. Rev."},{"key":"2750_CR11","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s40618-018-0903-3","volume":"42","author":"RM Ruggeri","year":"2019","unstructured":"R.M. Ruggeri, A. Campenn\u00ec, G. Giuffrida, P. Trimboli, L. Giovanella, F. Trimarchi, S. Cannav\u00f2, Endocrine and metabolic adverse effects of immune checkpoint inhibitors: an overview (what endocrinologists should know). J. Endocrinol. Investig. 42, 199\u2013205 (2019)","journal-title":"J. Endocrinol. Investig."},{"key":"2750_CR12","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","volume":"22","author":"M Freeman-Keller","year":"2016","unstructured":"M. Freeman-Keller, Y. Kim, H. Cronin, A. Richards, G. Gibney, J.S. Weber, Nivolumab in Resected and Unresectable Metastatic Melanoma: characteristics of Immune-Related Adverse Events and Association with Outcomes. Clin. Cancer Res. 22, 886\u2013894 (2016)","journal-title":"Clin. Cancer Res."},{"key":"2750_CR13","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s40618-019-01112-8","volume":"43","author":"EM Presotto","year":"2020","unstructured":"E.M. Presotto, G. Rastrelli, I. Desideri, V. Scotti, S. Gunnella, N. Pimpinelli, E. Vaccher, A. Bearz, F. Di Costanzo, M. Brugia et al. Endocrine toxicity in cancer patients treated with nivolumab or pembrolizumab: results of a large multicentre study. J. Endocrinol. Investig. 43, 337\u2013345 (2020)","journal-title":"J. Endocrinol. Investig."},{"key":"2750_CR14","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.it.2016.04.010","volume":"37","author":"PE Hughes","year":"2016","unstructured":"P.E. Hughes, S. Caenepeel, L.C. Wu, Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer. Trends Immunol. 37, 462\u2013476 (2016)","journal-title":"Trends Immunol."},{"key":"2750_CR15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.critrevonc.2019.05.015","volume":"141","author":"A Jannin","year":"2019","unstructured":"A. Jannin, N. Penel, M. Ladsous, M.C. Vantyghem, C. Do Cao, Tyrosine kinase inhibitors and immune checkpoint inhibitors-induced thyroid disorders. Crit. Rev. Oncol. Hematol. 141, 23\u201335 (2019)","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"2750_CR16","doi-asserted-by":"publisher","first-page":"225","DOI":"10.14740\/jocmr3750","volume":"11","author":"R Bajwa","year":"2019","unstructured":"R. Bajwa, A. Cheema, T. Khan, A. Amirpour, A. Paul, S. Chaughtai, S. Patel, T. Patel, J. Bramson, V. Gupta et al. Adverse Effects of Immune Checkpoint Inhibitors (Programmed Death-1 Inhibitors and Cytotoxic T-Lymphocyte-Associated Protein-4 Inhibitors): results of a Retrospective Study. J. Clin. Med. Res. 11, 225\u2013236 (2019)","journal-title":"J. Clin. Med. Res."},{"key":"2750_CR17","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/s40425-019-0754-2","volume":"7","author":"Y Zhai","year":"2019","unstructured":"Y. Zhai, X. Ye, F. Hu, J. Xu, X. Guo, Y. Zhuang, J. He, Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system. J. Immunother. Cancer 7, 286 (2019)","journal-title":"J. Immunother. Cancer"},{"key":"2750_CR18","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s40618-019-01105-7","volume":"43","author":"L Scappaticcio","year":"2020","unstructured":"L. Scappaticcio, M. Castellana, C. Virili, G. Bellastella, M. Centanni, S. Cannav\u00f2, A. Campenn\u00ec, R.M. Ruggeri, L. Giovanella, P. Trimboli, Alemtuzumab-induced thyroid events in multiple sclerosis: a systematic review and meta-analysis. J. Endocrinol. Investig. 43, 219\u2013229 (2020)","journal-title":"J. Endocrinol. Investig."},{"key":"2750_CR19","doi-asserted-by":"publisher","first-page":"101411","DOI":"10.1016\/j.beem.2020.101411","volume":"34","author":"R Percik","year":"2020","unstructured":"R. Percik, Y. Shoenfeld, Check point inhibitors and autoimmunity: why endocrinopathies and who is prone to? Best. Pract. Res. Clin. Endocrinol. Metab. 34, 101411 (2020)","journal-title":"Best. Pract. Res. Clin. Endocrinol. Metab."},{"key":"2750_CR20","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/cen.13297","volume":"86","author":"DL Morganstein","year":"2017","unstructured":"D.L. Morganstein, Z. Lai, L. Spain, S. Diem, D. Levine, C. Mace, M. Gore, J. Larkin, Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma. Clin. Endocrinol. (Oxf.) 86, 614\u2013620 (2017)","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"2750_CR21","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1530\/EJE-17-0810","volume":"178","author":"ES Scott","year":"2018","unstructured":"E.S. Scott, G.V. Long, A. Guminski, R.J. Clifton-Bligh, A.M. Menzies, V.H. Tsang, The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma. Eur. J. Endocrinol. 178, 175\u2013182 (2018)","journal-title":"Eur. J. Endocrinol."},{"key":"2750_CR22","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1158\/2326-6066.CIR-17-0208","volume":"5","author":"H Lee","year":"2017","unstructured":"H. Lee, F.S. Hodi, A. Giobbie-Hurder, P.A. Ott, E.I. Buchbinder, R. Haq, S. Tolaney, R. Barroso-Sousa, K. Zhang, H. Donahue et al. Characterization of thyroid disorders in patients receiving immune checkpoint inhibition therapy. Cancer Immunol. Res. 5, 1133\u20131140 (2017)","journal-title":"Cancer Immunol. Res."},{"key":"2750_CR23","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1200\/JCO.2017.77.0305","volume":"36","author":"GC Leonardi","year":"2018","unstructured":"G.C. Leonardi, J.F. Gainor, M. Altan, S. Kravets, S.E. Dahlberg, L. Gedmintas, R. Azimi, H. Rizvi, J.W. Riess, M.D. Hellmann et al. Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders. J. Clin. Oncol. 36, 1905\u20131912 (2018)","journal-title":"J. Clin. Oncol."},{"key":"2750_CR24","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ejca.2017.12.008","volume":"91","author":"FX Danlos","year":"2018","unstructured":"F.X. Danlos, A.L. Voisin, V. Dyevre, J.M. Michot, E. Routier, L. Taillade, S. Champiat, S. Aspeslagh, J. Haroche, L. Albiges et al. Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. Eur. J. Cancer 91, 21\u201329 (2018)","journal-title":"Eur. J. Cancer"},{"key":"2750_CR25","doi-asserted-by":"publisher","first-page":"4431","DOI":"10.1210\/jc.2016-2300","volume":"101","author":"J De Filette","year":"2016","unstructured":"J. De Filette, Y. Jansen, M. Schreuer, H. Everaert, B. Velkeniers, B. Neyns, B. Bravenboer, Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab. J. Clin. Endocrinol. Metab. 101, 4431\u20134439 (2016)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2750_CR26","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s40618-017-0772-1","volume":"41","author":"F Guaraldi","year":"2018","unstructured":"F. Guaraldi, R. La Selva, M.T. Sam\u00e0, V. D\u2019Angelo, D. Gori, P. Fava, M.T. Fierro, P. Savoia, E. Arvat, Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution. J. Endocrinol. Investig. 41, 549\u2013556 (2018)","journal-title":"J. Endocrinol. Investig."},{"key":"2750_CR27","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1210\/jc.2017-00448","volume":"102","author":"DA Delivanis","year":"2017","unstructured":"D.A. Delivanis, M.P. Gustafson, S. Bornschlegl, M.M. Merten, L. Kottschade, S. Withers, A.B. Dietz, M. Ryder, Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms. J. Clin. Endocrinol. Metab. 102, 2770\u20132780 (2017)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2750_CR28","first-page":"1035","volume":"31","author":"T Maekura","year":"2017","unstructured":"T. Maekura, M. Naito, M. Tahara, N. Ikegami, Y. Kimura, S. Sonobe, T. Kobayashi, T. Tsuji, S. Minomo, A. Tamiya et al. Predictive factors of nivolumab induced hypothyroidism in patients with non-small cell lung cancer. Vivo 31, 1035\u20131039 (2017)","journal-title":"Vivo"},{"key":"2750_CR29","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa053007","volume":"354","author":"H Gogas","year":"2006","unstructured":"H. Gogas, J. Ioannovich, U. Dafni, C. Stavropoulou-Giokas, K. Frangia, D. Tsoutsos, P. Panagiotou, A. Polyzos, O. Papadopoulos, A. Stratigos et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N. Engl. J. Med. 354, 709\u2013718 (2006)","journal-title":"N. Engl. J. Med."},{"key":"2750_CR30","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/ijc.28973","volume":"136","author":"A De Remigis","year":"2015","unstructured":"A. De Remigis, T.D. De Gruijl, J.N. Uram, S.C. Tzou, S. Iwama, M.V. Talor, T.D. Armstrong, S.J. Santegoets, S.F. Slovin, L. Zheng et al. Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival. Int. J. Cancer 136, 127\u2013137 (2015)","journal-title":"Int. J. Cancer"},{"key":"2750_CR31","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1093\/annonc\/mdw640","volume":"28","author":"JC Osorio","year":"2017","unstructured":"J.C. Osorio, A. Ni, J.E. Chaft, R. Pollina, M.K. Kasler, D. Stephens, C. Rodriguez, L. Cambridge, H. Rizvi, J.D. Wolchok et al. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann. Oncol. 28, 583\u2013589 (2017)","journal-title":"Ann. Oncol."},{"key":"2750_CR32","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1089\/thy.2019.0250","volume":"30","author":"A Kotwal","year":"2020","unstructured":"A. Kotwal, L. Kottschade, M. Ryder, Thyroid 30, 177\u2013184 (2020)","journal-title":"Thyroid"},{"key":"2750_CR33","doi-asserted-by":"publisher","first-page":"107296","DOI":"10.1016\/j.intimp.2020.107296","volume":"91","author":"Y Zhou","year":"2021","unstructured":"Y. Zhou, R. Xia, H. Xiao, D. Pu, Y. Long, Z. Ding, J. Liu, X. Ma, Thyroid function abnormality induced by PD-1 inhibitors have a positive impact on survival in patients with non-small cell lung cancer. Int Immunopharmacol. 91, 107296 (2021)","journal-title":"Int Immunopharmacol."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-021-02750-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-021-02750-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-021-02750-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T05:31:44Z","timestamp":1631597504000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-021-02750-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,25]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["2750"],"URL":"https:\/\/doi.org\/10.1007\/s12020-021-02750-w","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,25]]},"assertion":[{"value":"7 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the AOU Careggi ethics committee and was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}